Is history repeating itself? Suda who bought out the rights to...

Is history repeating itself? Suda who bought out the rights to NovaDels IP are they going down the same path in terms of a deal with Pfizer. The following article came out just under ten years ago. It makes reference to Viagra being considered as an OTC drug. Pure speculation on my part but it would make sense that one of the OTC drugs that is being considered is Viagra. If this is the case todays announcement could be the start of an upward momentum in the share price.
A good announcement but could have been great with more detail regarding the agreement.
Would like to see a break and close above 2.7 this is about the 4th time it has been tested and failed. A disappointing close today but I would expect further upward momentum with more deals to come. Charts are looking positive would be great if someone could post an update. Looking forward to the next few weeks. DYOR.
Are NovaDel and Pfizer Collaborating on a Viagra Spray?
Feb. 14, 2007 4:58 AM ET
H.S. Ayoub
A British business magazine, published an article early January on rumors that Pfizer (NYSE may have contacted NovaDel Pharma () to initiate research into the development of a Viagra spray.
Update: 11/01/07 - Since this article went up on our website on Wednesday evening, a central part of the story, that Pfizer is considering an over-the-counter Viagra, has been publicly confirmed by the firm for the first time.
A spokeswoman told Reuters: "As with many of our products, Pfizer has routinely evaluated a number of options (for Viagra), including different formulations, new indications, over-the-counter, etc., and continues to do so." This is the first time Pfizer has admitted considering an OTC version of the drug and is a significant development for the industry.
She continues:
Our information that Novadel is researching a spray version of Pfizer's Viagra drug was obtained in a conversation with a source who works at Novadel. This individual told The Business: "We have also been working on a spray version of Viagra." The individual said that this was one of several products the company is working on.
She also made it clear that both companies were told that this story would be published, but no one denied it. So she published it, only to have executives from both companies deny it to Dow Jones later.
When the original story appeared on the website it ignited shares of Novadel from the $1.40s to the $1.80s within a few days. That was not such a spectacular jump especially since Novadel stock did make it to almost $2 a couple of months before on the FDA approval news.